NCT00471133View on ClinicalTrials.gov

Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Melanoma (Skin)Intraocular Melanoma
Interventions
BIOLOGICAL

Xenogeneic Tyrosinase DNA Vaccine

DEVICE

TriGrid Delivery System for Intramuscular Electroporation

Trial Locations (1)

10021

Memorial Sloan Kettering Cancer Center, New York

Sponsors
All Listed Sponsors
collaborator

Memorial Sloan Kettering Cancer Center

OTHER

lead

Ichor Medical Systems Incorporated

INDUSTRY

NCT00471133 - Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation | Biotech Hunter | Biotech Hunter